[{"id":"bc600932-edcc-4a77-8717-8ae887e370be","acronym":"HERCREEM","url":"https://clinicaltrials.gov/study/NCT00889954","created_at":"2021-01-18T03:24:25.584Z","updated_at":"2024-07-02T16:37:06.790Z","phase":"Phase 1","brief_title":"Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy","source_id_and_acronym":"NCT00889954 - HERCREEM","lead_sponsor":"Baylor College of Medicine","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TGFBeta resistant HER2/EBV-CTLs"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 01/21/2018","study_completion_date":" 01/21/2018","last_update_posted":"2018-09-18"}]